The MAT Act has been introduced in the 117th congress and would eliminate the burdensome x waiver which requires that a health care practitioner apply for a separate waiver through the DEA to dispense certain narcotic drugs (e.g., buprenorphine) for substance use disorder treatment. The MAT Act would increase treatment access for patients to medication assisted treatment and make it easier for clinicians to provide substance use disorder treatment to their patients.
SPEAKERS
Doug Huynh, JD, as our new federal lobbyist and primary legislative advocate on Capitol Hill. Doug comes to ASHP with extensive experience from the Society of Interventional Radiology, where he worked for 12 years as Director of Government and Policy Affairs. Doug also served as a lawyer and lobbyist in a number of other healthcare-related organizations. He has an in-depth understanding of the healthcare landscape and the issues that impact pharmacists, physicians, healthcare organizations, and other providers, as well as excellent relationships on Capitol Hill and a strong knowledge of the political process.
Bayli Larson, PharmD, MS, BCPS is strategic initiatives associate at ASHP. In her role she helps manage and lead a variety of collaborative cross-organizational strategic activities to help advance ASHP’s mission and vision and is also co-coordinator of the ASHP Executive Fellowship in Association Leadership and Management. She completed her PGY1 residency at UCHealth Memorial Hospital in Colorado Springs, Colo., and earned her Pharm.D. from the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences.